GO:0043509 activin A complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043509 (activin A complex) is a cellular_component defined as a nonsteroidal regulator composed of two covalently linked inhibin beta-A subunits.
• Activin A is a homodimer of inhibin beta-A (INHBA) and signals through activin type II receptors to regulate growth, differentiation, and tissue homeostasis.
• Dysregulated activin A signaling is implicated in fibrodysplasia ossificans progressiva, cardiac aging and heart failure, and ischemia-reperfusion injury.
• Follistatin and inhibin A antagonize activin A, and their complexes modulate ligand availability and receptor activation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of INHBA and activin A complex function.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study activin A complex biology.
Description
The activin A complex (GO:0043509) is a secreted, disulfide-linked homodimer of inhibin beta-A subunits that acts as a nonsteroidal regulator of diverse biological processes. It belongs to the transforming growth factor beta (TGF-beta) superfamily and signals through activin type II receptors to control cell proliferation, differentiation, and tissue remodeling. Because activin A is a central node in developmental and homeostatic signaling, its dysregulation is linked to a broad spectrum of human diseases, including fibrodysplasia ossificans progressiva, cardiac aging and heart failure, and ischemia-reperfusion injury. Understanding the composition, assembly, and regulation of the activin A complex is therefore essential for both basic developmental biology and therapeutic development. This article integrates the QuickGO definition of GO:0043509 with verified PubMed literature to provide a research-grade overview of the activin A complex, its key genes, disease relevance, and the CRISPR-based methods used to study it.
activin A complex At A Glance
| GO ID | GO:0043509 |
|---|---|
| GO term | activin A complex |
| Ontology | cellular_component |
| Synonym | None listed in QuickGO |
| Major function | Nonsteroidal regulator composed of two covalently linked inhibin beta-A subunits; acts as a secreted TGF-beta superfamily ligand |
| Subunit composition | Homodimer of inhibin beta-A (INHBA) subunits |
| Covalent linkage | Disulfide-linked dimer |
| Signaling receptors | Activin type II receptors (ACVR2A/ACVR2B) |
| Antagonists | Follistatin and inhibin A |
What Is GO:0043509?
According to QuickGO, GO:0043509 (activin A complex) is a cellular_component defined as a nonsteroidal regulator composed of two covalently linked inhibin beta-A subunits, sometimes known as activin beta-A or activin/inhibin beta-A. In other words, the activin A complex is a homodimeric protein assembly of two inhibin beta-A (INHBA) polypeptides joined by covalent bonds, which functions as a secreted signaling ligand.
Why Is activin A complex Important in Cell Biology?
The activin A complex is a critical regulator of cell growth, differentiation, and tissue homeostasis, and its dysregulation contributes to a wide range of human diseases, including fibrodysplasia ossificans progressiva, cardiac aging and heart failure, and ischemia-reperfusion injury. Because activin A signals through activin type II receptors, it has become a therapeutic target for conditions characterized by excessive or aberrant TGF-beta superfamily signaling. Studying the activin A complex therefore provides mechanistic insight into developmental biology, tissue repair, and disease pathogenesis, and supports the development of targeted interventions.
• Activin A is a key TGF-beta superfamily ligand that regulates cell proliferation, differentiation, and tissue homeostasis.
• Dysregulated activin A signaling is implicated in fibrodysplasia ossificans progressiva, a rare genetic disorder of heterotopic ossification.
• Activin type II receptor signaling contributes to cardiac aging and heart failure, making activin A a therapeutic target.
• Activin A is involved in ischemia-reperfusion injury, a major cause of tissue damage in stroke and myocardial infarction.
• Follistatin and inhibin A antagonize activin A, and their complexes modulate ligand availability and receptor activation.
• Activin A is used in directed differentiation protocols for human pluripotent stem cells, including intestinal tissue engineering.
• Activin E, a related ligand, signals through activin receptor-like kinase 7, highlighting the diversity of activin signaling.
• CRISPR-based models enable causal dissection of INHBA and activin A complex function in health and disease.
Structure and Composition of activin A complex
Subunit composition and covalent linkage
In simple terms: The activin A complex is made of two identical protein subunits that are chemically linked together.
The activin A complex is a homodimer composed of two inhibin beta-A (INHBA) subunits that are covalently linked, typically through disulfide bonds. This covalent linkage stabilizes the dimer and is essential for its biological activity as a secreted ligand.
Assembly and secretion
In simple terms: The two subunits are produced inside the cell, join together, and are then released outside the cell.
Inhibin beta-A subunits are synthesized as precursor proteins that undergo proteolytic processing and dimerization before secretion. The mature activin A complex is secreted and can act locally or systemically on target cells expressing activin type II receptors.
Latent complex and extracellular regulation
In simple terms: Some TGF-beta family members are kept inactive until they are released from a latent complex.
Latent TGF-beta structures and activation mechanisms provide a paradigm for how TGF-beta superfamily ligands, including activin A, can be stored in latent complexes and activated extracellularly. This regulation ensures that activin A signaling is tightly controlled in space and time.
Antagonism by follistatin and inhibin A
In simple terms: Other proteins can bind to activin A and block its activity.
Follistatin forms a stable complex with inhibin A that does not interfere with activin A antagonism, indicating that follistatin can sequester activin A and modulate its availability. Inhibin A also antagonizes activin A signaling, providing an additional layer of regulation.
Key Genes Involved in GO:0043509 activin A complex
The following genes and proteins are central to the biology of the activin A complex (GO:0043509) and its signaling network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INHBA | Encodes the inhibin beta-A subunit that forms the activin A homodimer | Core component of GO:0043509; knockout and overexpression models dissect activin A function |
| ACVR2A | Activin type II receptor A that binds activin A | Mediates activin A signaling; target for functional studies |
| ACVR2B | Activin type II receptor B that binds activin A | Mediates activin A signaling; target for functional studies |
| ACVR1 | Activin receptor-like kinase 1 (ALK1) involved in TGF-beta superfamily signaling | Implicated in fibrodysplasia ossificans progressiva and activin A targeting |
| FST | Follistatin, an activin A antagonist | Forms stable complexes with inhibin A and modulates activin A activity |
| INHA | Inhibin alpha subunit that forms inhibin A | Inhibin A antagonizes activin A signaling |
| INHBB | Inhibin beta-B subunit that can form activin B and AB dimers | Related ligand with distinct signaling properties |
| INHBE | Inhibin beta-E subunit that forms activin E | Signals through activin receptor-like kinase 7 |
| SMAD2 | Intracellular transducer of activin A signaling | Downstream effector of activin type II receptor signaling |
| SMAD3 | Intracellular transducer of activin A signaling | Downstream effector of activin type II receptor signaling |
| SMAD4 | Common SMAD co-mediator of TGF-beta superfamily signaling | Central node in activin A signal transduction |
| FKBP1A | Immunophilin that regulates TGF-beta superfamily receptor signaling | Modulates activin receptor signaling |
| LTBP1 | Latent TGF-beta binding protein | Regulates latent complex formation and activation |
| GDF11 | Related TGF-beta superfamily ligand | Shares signaling components with activin A |
| MSTN | Myostatin, a TGF-beta superfamily ligand | Antagonized by follistatin and related to activin A biology |
| BMP4 | Bone morphogenetic protein 4 | Interacts with activin A signaling in differentiation |
| SOX17 | Transcription factor involved in endoderm differentiation | Used in activin A-driven differentiation protocols |
| CDX2 | Intestinal transcription factor | Induced by activin A in directed differentiation |
How Is activin A complex Regulated?
The activin A complex is regulated at multiple levels, including ligand biosynthesis, covalent dimerization, secretion, and extracellular antagonism by follistatin and inhibin A. Latent complex formation and activation provide an additional layer of control, as described for TGF-beta superfamily ligands. Activin type II receptor signaling is also modulated by intracellular proteins such as FKBP1A and SMAD effectors, which fine-tune downstream responses.
activin A complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| INHBA | Fibrodysplasia ossificans progressiva; heterotopic ossification | Knockout and overexpression cell models |
| ACVR2A | Cardiac aging and heart failure | Point-mutation and knockout models |
| ACVR2B | Cardiac aging and heart failure | Knockout and knock-in models |
| FST | Muscle wasting and metabolic disorders | Overexpression and knockout models |
| INHBE | Metabolic and muscle homeostasis | Knockout and overexpression models |
Fibrodysplasia ossificans progressiva (FOP)
Activin A has become a therapeutic target in fibrodysplasia ossans progressiva, a rare genetic disorder characterized by progressive heterotopic ossification. Dysregulated activin A signaling through activin receptors contributes to abnormal bone formation, and blocking activin A is being explored as a treatment strategy.
Cardiac aging and heart failure
Activin type II receptor signaling has been implicated in cardiac aging and heart failure, where increased activin A signaling promotes pathological cardiac remodeling. Targeting activin A signaling may therefore offer therapeutic benefit in heart failure.
Ischemia-reperfusion injury
Ischemia-reperfusion injury involves complex molecular mechanisms, and TGF-beta superfamily signaling, including activin A, contributes to tissue damage and repair responses. Modulating activin A signaling is a potential therapeutic approach in ischemia-reperfusion injury.
Metabolic and musculoskeletal conditions
Activin A and related ligands such as myostatin and activin E influence muscle and metabolic homeostasis, and their signaling is being investigated in conditions such as sarcopenia and weight loss-associated muscle loss. Follistatin-mediated antagonism of activin A is relevant to these processes.
From activin A complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does INHBA loss abolish activin A complex formation? | INHBA knockout cell line |
| Does a specific point mutation in INHBA alter dimerization or secretion? | Point-mutation knock-in cell line |
| Can tagged INHBA be used to track activin A complex localization? | Tagged knock-in cell line |
| Does INHBA overexpression increase activin A signaling? | Overexpression cell line |
| Does ACVR2A/ACVR2B knockout block activin A signaling? | Receptor knockout cell line |
| Does FST overexpression antagonize activin A activity? | FST overexpression cell line |
How to Study the activin A complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Testing requirement for activin A complex components |
| Point mutation | Effect of specific amino acid changes | Dissecting dimerization or receptor-binding interfaces |
| Knock-in tagging | Protein localization and interactions | Tracking activin A complex in cells |
| Overexpression | Gain-of-function effects | Increasing activin A signaling |
| Co-immunoprecipitation | Protein-protein interactions | Detecting inhibin beta-A dimers and follistatin complexes |
| SMAD reporter assay | Downstream signaling activity | Measuring activin A pathway activation |
| RNA sequencing | Transcriptional changes | Identifying activin A target genes |
| Mass spectrometry | Protein identification and quantification | Characterizing secreted activin A complexes |
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes that regulate activin A complex formation, secretion, and signaling. Library screening enables unbiased discovery of modifiers of activin A pathway activity.
Biochemical and proteomic analysis
Co-immunoprecipitation, Western blotting, and mass spectrometry can detect the covalent dimerization of inhibin beta-A subunits and identify interacting proteins such as follistatin. Proteomic profiling of secreted ligands can quantify activin A complex levels.
Transcriptional and signaling assays
SMAD-responsive luciferase reporters and RNA sequencing can measure downstream transcriptional responses to activin A signaling. These assays are used to assess the functional impact of genetic perturbations.
Imaging and localization studies
Fluorescence microscopy and tagged knock-in approaches can visualize the subcellular localization and secretion of the activin A complex. Live-cell imaging can track dimer assembly and release.
How CRISPR Can Be Used to Study GO:0043509 activin A complex
Knockout
CRISPR knockout of INHBA eliminates the inhibin beta-A subunit, abolishing formation of the activin A complex and providing a clean loss-of-function model to study its role in development and disease. Knockout of ACVR2A or ACVR2B blocks receptor-mediated activin A signaling.
Point Mutation
Point mutations in INHBA can be introduced to dissect the residues required for covalent dimerization, secretion, or receptor binding. Such models help distinguish structural requirements from downstream signaling effects.
Knock-in
Knock-in of epitope tags or fluorescent proteins into the endogenous INHBA locus enables tracking of activin A complex expression, localization, and secretion under native regulatory control. Knock-in of disease-associated mutations can model pathological signaling.
Overexpression
Overexpression of INHBA increases activin A complex levels and signaling, allowing gain-of-function studies in differentiation and disease models. Overexpression of antagonists such as FST can suppress activin A activity.
How EDITGENE Supports activin A complex Research
Researchers studying activin A complex-related genes often need to determine whether a candidate gene is causally involved in ligand assembly, secretion, or downstream signaling. EDITGENE provides publication-ready CRISPR cell models and bioinformatics services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for activin A complex research.
Frequently Asked Questions About activin A complex
What is the activin A complex?
The activin A complex (GO:0043509) is a nonsteroidal regulator composed of two covalently linked inhibin beta-A subunits, also known as activin beta-A or activin/inhibin beta-A.
What genes are involved in the activin A complex?
The core gene is INHBA, which encodes the inhibin beta-A subunit; related genes include ACVR2A, ACVR2B, FST, and INHA.
What is the function of GO:0043509?
GO:0043509 describes a secreted TGF-beta superfamily ligand that regulates cell growth, differentiation, and tissue homeostasis through activin type II receptors.
How is activin A signaling regulated?
Activin A signaling is regulated by ligand biosynthesis, covalent dimerization, secretion, and extracellular antagonists such as follistatin and inhibin A.
What diseases are associated with activin A?
Activin A is implicated in fibrodysplasia ossificans progressiva, cardiac aging and heart failure, ischemia-reperfusion injury, and metabolic/muscle conditions.
How can I study the activin A complex in the lab?
CRISPR knockout, point-mutation, knock-in, and overexpression models combined with biochemical and transcriptional assays are commonly used.
What is the role of follistatin in activin A biology?
Follistatin binds and antagonizes activin A, and forms stable complexes with inhibin A that do not interfere with activin A antagonism.
Is activin A a therapeutic target?
Yes, activin A has become a therapeutic target in fibrodysplasia ossificans progressiva and is being investigated in cardiac and metabolic diseases.
What receptors does activin A signal through?
Activin A signals through activin type II receptors, including ACVR2A and ACVR2B, activating SMAD2/3-dependent transcription.
Can CRISPR be used to model activin A-related diseases?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of activin A pathway genes in disease contexts.
Conclusion
The activin A complex (GO:0043509) is a covalently linked homodimer of inhibin beta-A subunits that functions as a key TGF-beta superfamily ligand in development, tissue homeostasis, and disease. Its dysregulation is linked to fibrodysplasia ossificans progressiva, cardiac aging and heart failure, and ischemia-reperfusion injury, making it an important therapeutic target. CRISPR-based cell models and screening approaches provide powerful tools to dissect the molecular mechanisms of activin A complex assembly, signaling, and regulation.
References
- 1. Zhang M et al.. 2024. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.. Signal Transduct Target Ther 9(1):12 PMID: 38185705
- 2. Vestal KA et al.. 2024. Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7.. Biochem J 481(7):547-564 PMID: 38533769
- 3. Spence JR et al.. 2011. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro.. Nature 470(7332):105-9 PMID: 21151107
- 4. Srinivasan D et al.. 2024. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.. Biomolecules 14(1) PMID: 38254701
- 5. Shi M et al.. 2011. Latent TGF-β structure and activation.. Nature 474(7351):343-9 PMID: 21677751
- 6. Pantazopoulos D et al.. 2025. GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review.. Diabetes Res Clin Pract 229:112924 PMID: 41022269
- 7. Roh JD et al.. 2019. Activin type II receptor signaling in cardiac aging and heart failure.. Sci Transl Med 11(482) PMID: 30842316
- 8. Kappes EC et al.. 2023. Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism.. Endocrinology 164(3) PMID: 36718082
